BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder

By WebmasterJune 27, 2018November 1st, 2024No Comments

Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Top-Line Data Expected in First Half of 2019

See more here

Previous PostRobert Wicke Appointed as New CEO of Halo Labs
Next PostIView Therapeutics Closes its A round financing to move forward IView-1201, a novel sustain release povidone iodine gel forming solution, into phase II clinical trials for the treatment of adenoviral conjunctivitis

Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostRobert Wicke Appointed as New CEO of Halo Labs

Next PostIView Therapeutics Closes its A round financing to move forward IView-1201, a novel sustain release povidone iodine gel forming solution, into phase II clinical trials for the treatment of adenoviral conjunctivitis